RWC-340B Seeking Managing Director
Summary The Managing Director of the Ryan White Clinics for 340B Access Coalition (RWC-340B) reports to the Executive Director of United Partners for Human Services (UPHS), the managed service organization…
Johnson & Johnson is the 16th Manufacturer to Restrict Access to 340B Prices at Contract Pharmacies
By letter dated March 21, 2021, Johnson & Johnson (J&J) announced that, effective May 2, 2022, it will no longer honor bill-to/ship-to orders for contract pharmacy arrangements with hospitals unless…
RWC-340B Sends Gilead Letter Requesting Exceptions for MAP/PAP Policies
Please see the attached letter to Mr. Charles Clapton, VP of Federal Governmental Affairs with Gilead from RWC-340B President, Shannon Stephenson on behalf of RWC-340B requesting exceptions to MAP/PAP Policies. Should you…
Pfizer and GSK Announce Policies to Restrict Access to 340B Drugs at Contract Pharmacies; Novo Nordisk Modifies Its Policy
Pfizer and GlaxoSmithKline (“GSK”) are the 13th and 14th manufacturers, respectively, to restrict 340B pricing on drugs shipped to contract pharmacies. Novo Nordisk, which previously restricted access to 340B pricing to one…
POTUS Pledges to Enforce 340B Program
President Joe Biden yesterday during a major speech on drug pricing reform applauded U.S. Rep. Abigail Spanberger (D-Va.) for being “relentless in making sure” that the 340B statute “is actually…
Spanberger to HHS: Hold Drug Companies Accountable for Breaking the Law, Crack Down on Illegal Price Hikes
In response to a rash of reckless decisions by pharmaceutical companies, U.S. Representative Abigail Spanberger is leading a bipartisan effort to protect the 340B Drug Pricing Program and prevent additional…
BMS is the 12th Manufacturer to Restrict Access to 340B Prices at Contract Pharmacies; Permits Designation of One Contract Pharmacy for Three Cancer Drugs
By email dated January 14, 2022, Bristol Myers Squibb (BMS) announced that, effective March 1, 2022, it will implement a new 340B contract pharmacy policy impacting two drug categories: non-immunomodulatory…
Second Sight Updates 340B ESP Terms of Use
In October 2021, Second Sight, the owner of 340B ESP, updated the Terms of Use (TOU) that covered entities must agree to when registering for the 340B ESP platform. There…
New AbbVie and Lilly Contract Pharmacy Policies
AbbVie is the 11th Manufacturer to Restrict Access to 340B Prices at Contract Pharmacies By letter dated December 29, 2021, AbbVie announced that, effective February 1, 2022, it will implement…